United Therapeutics Corpo... (UTHR)
NASDAQ: UTHR
· Real-Time Price · USD
307.19
-0.05 (-0.02%)
At close: Aug 29, 2025, 9:37 AM
-0.02% (1D)
| Bid | 306.77 |
| Market Cap | 13.89B |
| Revenue (ttm) | 3.08B |
| Net Income (ttm) | 1.24B |
| EPS (ttm) | 25.62 |
| PE Ratio (ttm) | 11.99 |
| Forward PE | 10.43 |
| Analyst | Buy |
| Ask | 307.98 |
| Volume | 14,910 |
| Avg. Volume (20D) | 653,517 |
| Open | 307.16 |
| Previous Close | 307.24 |
| Day's Range | 305.50 - 309.10 |
| 52-Week Range | 266.98 - 417.82 |
| Beta | 0.57 |
About UTHR
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol UTHR
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for UTHR stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
United Therapeutics Corporation is scheduled to release its earnings on
Oct 29, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+7.13%
United Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
2 months ago
-14.32%
United Therapeutics shares are trading lower in reaction to Insmed after its drug to treat rare lung disease met its primary endpoint and all secondary efficacy endpoints.
4 weeks ago · fool.com
Earnings Summary on United TherapeuticsEarnings Summary on United Therapeutics
4 weeks ago · seekingalpha.com
United Therapeutics Corporation (UTHR) Q2 2025 Earnings Call TranscriptUnited Therapeutics Corporation (NASDAQ:UTHR ) Q2 2025 Earnings Conference Call July 30, 2025 9:00 AM ET Company Participants C.Q. Deng - Corporate Participant Dewey Steadman - Head of Investor Relati...
